Q32 Bio Stock Revenue
| QTTB Stock | 25.44 0.89 3.63% |
Q32 Bio fundamentals help investors to digest information that contributes to Q32 Bio's financial success or failures. It also enables traders to predict the movement of Q32 Stock. The fundamental analysis module provides a way to measure Q32 Bio's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Q32 Bio stock.
| Last Reported | Projected for Next Year | ||
| Total Revenue | 1.2 M | 1.1 M |
Q32 | Revenue |
Q32 Bio Company Revenue Analysis
Q32 Bio's Revenue is income that a firm generates from business activities such us rendering services or selling goods to customers. It is a crucial part of a business and an essential item when evaluating a company's financial statements. Revenues from a firm's primary business operations can be reported on the income statement as sales revenue, net sales, or simply sales, depending on the industry in which a given company operates.
Current Q32 Bio Revenue | 1.16 M |
Most of Q32 Bio's fundamental indicators, such as Revenue, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Q32 Bio is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Historical and Projected quarterly revenue of Q32
Projected quarterly revenue analysis of Q32 Bio provides investors and stakeholders with an insight into the company's performance and growth prospects. When actual revenues of Q32 Bio match or exceed analyst estimates, it positively influences investor confidence and market perception, often leading to a rise in Q32 Bio's stock price.
Q32 Revenue Driver Correlations
Understanding the fundamental principles of building solid financial models for Q32 Bio is extremely important. It helps to project a fair market value of Q32 Stock properly, considering its historical fundamentals such as Revenue. Since Q32 Bio's main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Q32 Bio's historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Q32 Bio's interrelated accounts and indicators.
| -0.27 | -0.22 | -0.66 | -0.43 | -0.57 | ||
| -0.27 | 0.37 | 0.13 | 0.22 | -0.14 | ||
| -0.22 | 0.37 | -0.31 | 0.95 | 0.46 | ||
| -0.66 | 0.13 | -0.31 | -0.19 | 0.01 | ||
| -0.43 | 0.22 | 0.95 | -0.19 | 0.66 | ||
| -0.57 | -0.14 | 0.46 | 0.01 | 0.66 |
Click cells to compare fundamentals
Q32 Revenue Historical Pattern
Today, most investors in Q32 Bio Stock are looking for potential investment opportunities by analyzing not only static indicators but also various Q32 Bio's growth ratios. Consistent increases or drops in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's revenue growth rates may not be enough to decide which company is a better investment. That's why investors frequently use a static breakdown of Q32 Bio revenue as a starting point in their analysis.
Q32 Bio Revenue |
| Timeline |
Revenue is typically recorded when cash or cash equivalents are exchanged for services or goods and can include products or services discounts, promotions, as well as early payments on invoices or services rendered in advance.
| Competition |
Q32 Current Deferred Revenue
Current Deferred Revenue |
|
Based on the latest financial disclosure, Q32 Bio reported 1.16 M of revenue. This is 99.98% lower than that of the Biotechnology sector and 99.84% lower than that of the Health Care industry. The revenue for all United States stocks is 99.99% higher than that of the company.
Q32 Revenue Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Q32 Bio's direct or indirect competition against its Revenue to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Q32 Bio could also be used in its relative valuation, which is a method of valuing Q32 Bio by comparing valuation metrics of similar companies.Q32 Bio is currently under evaluation in revenue category among its peers.
Q32 Bio Current Valuation Drivers
We derive many important indicators used in calculating different scores of Q32 Bio from analyzing Q32 Bio's financial statements. These drivers represent accounts that assess Q32 Bio's ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of Q32 Bio's important valuation drivers and their relationship over time.
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Market Cap | 871.8M | 518.3M | 201.2M | 35.2M | 40.4M | 38.4M | |
| Enterprise Value | 818.1M | 316.3M | 174.0M | (2.8M) | (3.2M) | (3.1M) |
Q32 Fundamentals
| Operating Margin | 5.18 % | ||||
| Current Valuation | 468.77 M | ||||
| Shares Outstanding | 12.06 M | ||||
| Shares Owned By Insiders | 9.14 % | ||||
| Shares Owned By Institutions | 73.77 % | ||||
| Number Of Shares Shorted | 686.07 K | ||||
| Price To Book | 16.61 X | ||||
| Revenue | 1.16 M | ||||
| EBITDA | (86.5 M) | ||||
| Net Income | (112.96 M) | ||||
| Total Debt | 1.32 M | ||||
| Book Value Per Share | 2.79 X | ||||
| Cash Flow From Operations | (96.23 M) | ||||
| Short Ratio | 3.65 X | ||||
| Earnings Per Share | (4.50) X | ||||
| Target Price | 77.8 | ||||
| Number Of Employees | 42 | ||||
| Market Capitalization | 556.56 M | ||||
| Total Asset | 306.12 M | ||||
| Retained Earnings | (542.1 M) | ||||
| Net Asset | 306.12 M |
About Q32 Bio Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Q32 Bio's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Q32 Bio using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Q32 Bio based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Q32 Bio offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Q32 Bio's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Q32 Bio Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Q32 Bio Stock:Check out Q32 Bio Piotroski F Score and Q32 Bio Altman Z Score analysis. For information on how to trade Q32 Stock refer to our How to Trade Q32 Stock guide.You can also try the Efficient Frontier module to plot and analyze your portfolio and positions against risk-return landscape of the market..
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Q32 Bio. If investors know Q32 will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Q32 Bio listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (4.50) | Revenue Per Share (1.24) |
The market value of Q32 Bio is measured differently than its book value, which is the value of Q32 that is recorded on the company's balance sheet. Investors also form their own opinion of Q32 Bio's value that differs from its market value or its book value, called intrinsic value, which is Q32 Bio's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Q32 Bio's market value can be influenced by many factors that don't directly affect Q32 Bio's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Q32 Bio's value and its price as these two are different measures arrived at by different means. Investors typically determine if Q32 Bio is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Q32 Bio's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.